Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2023-08-15
Target enrollment:
Participant gender:
Summary
The purpose of this first in human (FIH) trial is to characterize the safety and tolerability
of the SHP2 inhibitor TNO155 alone and in combination with EGF816 (nazartinib) and identify a
recommended dose for future studies in adult patients with advanced solid tumors in selected
indications.